Regulations covering public health should override personal rights and the country cannot wait any more for a good public health law. The health care industry, including institutions of medical education, hospitals and pharmaceutical businesses, have grown into behemoths that can do considerable harm in the absence of independent and effective regulatory systems. While there are no success stories in the regulation of any kind of industry in India, I will focus...

-Tehelka Justice Sujata Manohar on how the Biotechnology Bill is fundamentally flawed IN THE last few years, regulatory systems across the board have been undergoing an overhaul to fit the needs of a new era. Likewise, new laws are being chalked out to meet new needs, and several are receiving flak owing to the loopholes and regressive grounds on which these have been drafted. The relatively more recent one to regulate modern...

-The Hindustan Times Bollywood star Aamir Khan had two simple prescriptions for a Parliamentary committee to reduce high health costs for citizens. First, make doctors prescribe generic medicines rather than brands. Second, set up a regulator to ensure Big pharmaceutical don’t take over smaller ones and monopolise the medicine market. Khan and his team were invited on Thursday by the Parliamentary Standing Committee on Commerce headed by BJP MP Shanta Kumar, which...

-The Economic Times A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health. Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions. Last month, China amended its IP laws, allowing local companies to produce low-cost versions...

-The Economic Times   Pushed to the wall by an overly cautious drug regulator and an alarmist Indian government, clinical trial companies are looking at South East Asian countries to expand their business and escape the red tape of Indian authorities.  Clinical research companies (CROs), that were aspiring to become billion- dollar companies by 2010, had to rework their plans after a Parliamentary Standing Committee report questioned the allegedly unfair and unethical trials...